These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19369429)

  • 21. Oral treatments for type II diabetes in patients with cardiovascular disease.
    Brosnan R
    Cardiol Rev; 2003; 11(1):35-40. PubMed ID: 12493134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From hyperglycemia to the risk of cardiovascular disease.
    Leiter LA
    Rev Cardiovasc Med; 2006; 7 Suppl 2():S3-9. PubMed ID: 17224875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Molecular action of insulin-sensitizing agents].
    Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
    Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents.
    Ajjan RA; Grant PJ
    Diab Vasc Dis Res; 2006 Dec; 3(3):147-58. PubMed ID: 17160909
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factors associated with switching from oral hypoglycaemic agents to insulin therapy.
    Spoelstra JA; Stol RP; de Bruyne MC; Erkens JA; Herings RM; Leufkens HG; Grobbee DE
    Neth J Med; 2002 Jul; 60(6):243-8. PubMed ID: 12365467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diabetes treatments and risk of heart failure, cardiovascular disease, and all cause mortality: cohort study in primary care.
    Hippisley-Cox J; Coupland C
    BMJ; 2016 Jul; 354():i3477. PubMed ID: 27413012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society.
    Napoli R; Formoso G; Piro S; Targher G; Consoli A; Purrello F
    Nutr Metab Cardiovasc Dis; 2020 Oct; 30(11):1926-1936. PubMed ID: 32928628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cardiovascular effects of oral hypoglycemie drugs].
    Herrmann BL; Erbel R; Janssen OE; Mann K
    Herz; 2004 Aug; 29(5):510-8. PubMed ID: 15340737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular disease prevention strategies for type 2 diabetes mellitus.
    Katsiki N; Purrello F; Tsioufis C; Mikhailidis DP
    Expert Opin Pharmacother; 2017 Aug; 18(12):1243-1260. PubMed ID: 28685623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is metformin more than an oral hypoglycaemic agent?
    Vague P
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S5-7. PubMed ID: 14502095
    [No Abstract]   [Full Text] [Related]  

  • 32. [Glucose-independent impact of the glitazones on the cardiovascular outcome].
    Hanefeld M
    MMW Fortschr Med; 2005 Jan; 147(1-2):37-9. PubMed ID: 15704569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes.
    Erdmann E
    Int J Cardiol; 2006 Feb; 107(2):147-53. PubMed ID: 15975669
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes.
    Ovalle F
    Clin Ther; 2011 Apr; 33(4):393-407. PubMed ID: 21635987
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].
    Onuchin SG; Elsukova OS; Solov'ev OV; Onuchina EL
    Ter Arkh; 2010; 82(8):34-41. PubMed ID: 20873243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
    Christiansen AL; Madsbad S
    Ugeskr Laeger; 2002 Apr; 164(15):2022-4. PubMed ID: 11984999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Med; 2017 Jun; 130(6S):S18-S29. PubMed ID: 28526186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testosterone therapy of men with type 2 diabetes mellitus - a randomized, double-blinded, placebo-controlled study.
    Magnussen LV
    Dan Med J; 2017 Jul; 64(7):. PubMed ID: 28673384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological management of type 2 diabetes: what's new in 2017?
    Scheen AJ
    Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1383-1394. PubMed ID: 28879786
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.